In Boehringer-Ingelheim2017, sales revenue reached 18 billion 100 million euros, an increase of 15.7% over the same period, and the total expenditure on research and development exceeded 3 billion euros. It is estimated that 15 new drugs will be approved by Boehringer-Ingelheim in 2025.
In April 25, 2018, Boehringer-Ingelheim released its 2017 earnings report. The results showed that the company achieved net sales of nearly 18 billion 100 million euros in the past year, and increased by 15.7% after the exchange rate adjustment (+13.9% in euros). After excluding all the one-time effects from the exchange of Senofi’s business, the net sales of the company, after the exchange rate adjusted, increased by 6.1% (+4.4% in Euro). The company’s operating income is about 3 billion 500 million euros, with a net sales return of 19.3%.
At the same time, the company has achieved organic growth in all its business areas in 2017. Michael Schmelmer, the head of the company’s financial director and executive board, stressed, “it is particularly worth mentioning that the drug business is beyond our expectations, mainly due to our growth in the United States and emerging markets.” For 2018, the company is also optimistic that net sales will grow slightly.
People have achieved great success in drug business
In the field of human drug business, the company achieved six net sales of over 1 billion US dollars in 2017. They are respiratory drugs Spiriva (tiotropium bromide), anticoagulant Pradaxa (dabiaga ester), hypoglycemic agent Trajenta (leiglitine) and Jardiance (Don Glenn Jing), Ofev (Neda Knibb) for the treatment of idiopathic pulmonary fibrosis (IPF) and hypertension drug Micardis (Ti Mi Chatain).
In general, the net sales of the drug business, adjusted by the exchange rate, increased by 6.9%, with a total of more than 12 billion 600 million euros (the euro was increased to +5.0%), and the growth rate exceeded the market average. Net sales of human drug business account for about 70% of the company’s total net sales.
Excellent performance in animal health and Biopharmaceuticals
Animal health business contributed about 22% of the company’s net sales. Thanks to the additional net sales from Sanofi exchange, animal health business doubled its net sales in 2017 to 3 billion 900 million euros. In the field of biopharmaceutical contract production, the net sales of the company last year were 678 million euros, and the rate adjusted by the exchange rate was 10.7%, accounting for 4% of the total net sales of the company.
The overall strategy for human use of drug and animal health services
A key strategic objective of the company is to develop an overall strategy that benefits patients (including humans and animals). The “patient centred” digital project is an example. Boehringer-Ingelheim has now established the BI X digital laboratory and increased the scale of the Boehringer-Ingelheim venture capital fund from 100 million euros to 250 million euros, of which 50 million euros will be devoted to digital innovation projects.
R & D: continue to implement the established R & D route
At present, the company has a large number of similar first and breakthrough potential drug candidates, which can witness the success of the past research and development routes. As a R & D driven company, Boehringer-Ingelheim’s R & D costs accounted for 17% of net sales last year (equivalent to 20% of net sales of people), and by 2025 the company would invest more than 20 billion euros for the research and development of human drugs.
Huge R & D investment has also brought a number of R & D breakthroughs. Over the past four years, the company has received 14 regulatory approvals for multiple indications, including four new molecular compounds and four “breakthrough therapies” awarded by FDA in the United States. The company currently has 80 clinical and preclinical projects, of which 65% have the same first and breakthrough drug potential. It is expected that by 2025, 15 new drugs are expected to be approved, covering the areas of immune, central nervous system, tumors, respiratory systems, and cardiovascular metabolic diseases.
Each of the major R & D products line has its own bright spots.
- Immunology: IL-36 receptor inhibitors are expected to change the standard treatment of patients with immune mediated diseases.
- Oncology: the exploration of targeted therapies directly against the current tumor cell pathways of non effective drugs, more than 10 of the cancer products are currently in clinical trials.
- Central nervous system: expand the research project of PDE9 inhibitors to prevent relapse of schizophrenia and prevent the onset of mental disorders.
- Fibrosis (respiratory and cardiovascular metabolic diseases): a study of the application of compound Neda Knibb (nintedanib) in various fibrotic interstitial lung disease (ILDs); the company’s same leading compound, AOC3 inhibitor, is undergoing a clinical trial of phase II.
- Cardiovascular metabolic disease: a related phase III clinical trial was conducted to study the potential efficacy of Don Glenn Jing in helping diabetics and patients without diabetes to prevent chronic kidney disease and chronic heart failure.
Boehringer-Ingelheim’s global R & D team includes 8000 scientists, doctors and other contributors. At the same time, in order to support and complement its own R & D strength, the company is further strengthening external cooperation and expanding the scope of innovation partners. At present, the company has collaborated with more than 70 innovative partners, including universities, research institutes and biotechnology companies.
Strong two digit growth in China’s market
China is a very important market for Boehringer-Ingelheim. At present, the company has 5 bases and 15 offices in China, and has about 3600 employees. In 2017, China’s net sales reached a two digit strong growth rate, reaching nearly 43% after the exchange rate adjustment. Therefore, China is a very dynamic and fast-growing market for Boehringer-Ingelheim.
The human use of drugs has been a great success in China. Four drugs were approved in China in 2017, such as alafinii (alafinib), European Tang Jing (engiljing), double plus (telmisartan amlodipine) and Vigat (nidinib). In January 2017, with the successful integration of Melia, the company’s animal health business became the leader of Chinese multinationals. At the same time, the company is also developing bio pharmaceutical contract in China to provide first-class services for local and international companies. At present, Boehringer-Ingelheim is the first and only multinational company that provides contract services for biopharmaceutical production in China. The main customers are from China and other countries.
Over the past 20 years, Boehringer-Ingelheim has invested more than 200 million euros in China, and the company plans to invest 150 million euros between 2017 and 2022.
Founded in 1885, Boehringer-Ingelheim is still a family business and is one of the top 20 pharmaceutical companies in the world. Boehringer-Ingelheim has produced three business areas with drugs, animal health and bio pharmaceutical contracts, with around 50 thousand employees worldwide.
Boehringer-Ingelheim, a research and development – driven pharmaceutical company, has always been devoted to improving the health and quality of life of the patients, focusing on exploring the field of disease that has not yet emerged as an effective treatment, developing innovative therapies to help patients extend their lives. In the field of animal health, Boehringer-Ingelheim represents advanced prevention programs.